A promising new approach for the gene therapy of cancer is the introduction of the herpes simplex virus thymidine kinase (HSV tk) gene into tumour cells, where the HSV tk gene product converts the non-toxic prodrug ganciclovir (GCV) into its cytotoxic metabolite. We constructed a recombinant plasmid containing the HSV tk gene using standard molecular biology techniques in order to investigate whether the HSV tk/GCV enzyme/prodrug system could kill the human nasopharyngeal carcinoma cell line HNE-1. The recombinant plasmid pcDNA3.1(–) CMV.TK was transfected into the HNE-1 cells by electroporation. The expression of HSV tk by the transfected HNE-1/TK cells was confirmed by mRNA amplification and Western blotting. The growth of HNE-1/TK cells was inhibited by GCV in a dose-dependent manner. The HSV tk/GCV system also demonstrated a considerable bystander effect on co-cultured wild type HNE-1 cells. We conclude that the HSV tk/GCV system could be used as gene therapy for nasopharyngeal carcinoma.
KuriyamaSMasuiKSakamotoT: Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res1998; 18: 3399–3406.
2.
KanekoYTsukamotoA: Gene therapy of hepatoma: Bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett1995; 96: 105–110.
3.
MooltenFLWellsJMHeymanRA: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther1990; 1: 125–134.
4.
HirayamaT: Descriptive and analytical epidemiology of nasopharyngeal carcinoma cancer. IARC Sci Publ1978; 20: 167–189.
5.
TangYXuJLiuJ: Study of treating laryngeal cancer with suicide fusion gene CDglyTK in vitro. Chin Modern Med J2006; 16: 1766–1771.
6.
YeMXuG: Surgery of recurrent or residual nasopharyngeal carcinoma after radiotherapy. ZhongHuaErBiYanHouKeZaZhi1989; 24: 234–235 (in Chinese).
7.
ChenXChenCZhangH: The discussion of re-radiotherapy on recurrence of nasopharyngeal carcinoma after radiotherapy. ZhongHuaZhongLiuZaZhi1984; 6: 134–135 (in Chinese).
8.
WildnerOBlaeseRMCandottiF: Enzyme prodrug gene therapy: Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res1999; 59: 5233–5238.
9.
MizunoMRyukeYYoshidaJ: Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models. Cancer Gene Ther2002; 9: 825–829.
10.
Sa CunhaABonteEDuboisS: Inhibition of rat hepatocellular carcinoma tumor growth after multiple infusions of recombinant Ad. AFPtk followed by ganciclovir treatment. J Hepatol2002; 37: 222–230.
11.
HsiehCLGardnerTAMiaoL: Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene Ther2004; 11: 148–155.
12.
ChowKPLuHCChouHF: Induction of chemosensitivity in nasopharyngeal carcinoma cells using a human papillomavirus regulatory sequence and the thymidine kinase gene. J Biomed Sci2002; 9: 41–46.
13.
GermanoIMFableJGultekinSH: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol2003; 65: 279–289.
14.
FogarPGrecoEBassoD: Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol2003; 29: 721–730.
15.
MuramatsuTMizutaniYOhmoriY: Comparison of three nonviral transfection methods for foreign gene expression in early chicken embryos in ovo. Biochem Biophys Res Commun1997; 230: 376–380.
16.
LiYChenZ: The transfected effect comparison between electroporation and lipofection on cancer of the cervix. Nanhua Med Bull2006, 34: 526–529.
17.
OkabeSAraiTYamashitaH: Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J Cancer Res Clin Oncol2003; 129: 367–373.
18.
BlaszczykNMasriBAMawjiNR: Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res2004; 10: 1860–1869.
19.
MajumdarASHughesDELichtsteinerSP: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther2001; 8: 568–578.
20.
QiuZHarmsJSZhuJ: Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol2004; 78: 4224–4233.
21.
KongBWangWLiuC: Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo2003; 17: 153–156.
22.
LiuCSKongBXiaHH: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med2001; 3: 145–152.
23.
DilberMSPhelanAAintsA: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther1999; 6: 12–21.
